Francesco Siviero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Francesco Siviero has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Ali Muslimani
Department of Clinical, Surgical, Diagnostic and Pediatric Science, University of Pavia, Pavia, Italy, unipv.eu
3 shared publications - Raffaele Bruno
Infectious Diseases Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
3 shared publications - Angela Maria Di Matteo
Division of Infectious and Tropical Diseases, IRCCS S. Matteo Hospital Foundation, Pavia, Italy
2 shared publications - Armanda Leka
Department of Clinical Surgical Diagnostic and Pediatric Sciences University of Pavia Pavia Italy unipv.eu
2 shared publications - Pietro Valsecchi
SC Malattie Infettive I, I.R.C.C.S. Fondazione Policlinico San Matteo, Pavia, Italy
2 shared publications - Raffaella Lissandrin
Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Ophthalmological Medicine
- Vol. 2026 (1)
Disseminated Tuberculosis With Ocular Involvement After 12 Years of Anti–TNF‐ α Therapy
Background: Ocular tuberculosis (TB) is an uncommon yet potentially vision‐threatening manifestation of Mycobacterium tuberculosis , particularly difficult to diagnose in immunocompromised individuals. The increasing use of anti–tumor necrosis factor‐ α (anti–TNF‐ α ) agents has markedly heightened the risk of TB reactivation, often with disseminated or extrapulmonary involvement despite negative baseline screening. Case Presentation: We describe a 52‐year‐old woman with rheumatoid arthritis receiving long‐term adalimumab and methotrexate who developed disseminated TB with pulmonary, splenic, and ocular involvement after 12 years of anti–TNF‐ α therapy. Baseline screening had shown a negative tuberculin skin test and an indeterminate interferon‐ γ release assay. She presented with constitutional and respiratory symptoms, whereas chest computed tomography demonstrated diffuse micronodular infiltrates consistent with miliary TB. Microbiological confirmation was obtained via bronchoalveolar lavage. Ophthalmologic evaluation revealed bilateral choroidal granulomas with subretinal edema, leading to a diagnosis of ocular TB. Standard antitubercular therapy (ATT) was initiated but required modification due to drug‐induced liver injury. Adjunctive systemic corticosteroids were introduced after antimicrobial therapy and gradually tapered. The patient achieved progressive clinical, radiological, and ophthalmologic improvement, with gradual regression of choroidal lesions. Discussion: This case underscores the persistent long‐term risk of TB reactivation during prolonged anti–TNF‐ α therapy and highlights the limitations of current screening strategies in immunosuppressed patients. Ocular TB requires integration of systemic, clinical, and imaging findings; in this patient, microbiologically confirmed disseminated TB together with characteristic bilateral choroidal granulomas supported a definitive diagnosis. Management relies on prompt ATT, discontinuation of immunosuppression, and judicious use of adjunctive corticosteroids. Long‐term follow‐up is essential given the risk of persistent lesions and late recurrence. Reintroduction of biologic therapy may be feasible in selected cases but requires careful risk stratification. Conclusion: TB should remain a diagnostic consideration in patients receiving biologic therapy who develop compatible systemic or ocular manifestations, even after long‐term treatment and negative baseline screening. Close multidisciplinary collaboration is essential for the diagnosis and management of ocular TB in this population.
- 1 January 2026
- Published by Wiley in Case Reports in Ophthalmological Medicine
- Vol. 2026 (1)
Open AccessDisseminated Tuberculosis With Ocular Involvement After 12 Years of Anti–TNF‐ α Therapy
Background: Ocular tuberculosis (TB) is an uncommon yet potentially vision‐threatening manifestation of Mycobacterium tuberculosis , particularly difficult to diagnose in immunocompromised individuals. The increasing use of anti–tumor necrosis factor‐ α (anti–TNF‐ α ) agents has markedly heightened the risk of TB reactivation, often with disseminated or extrapulmonary involvement despite negative baseline screening. Case Presentation: We describe a 52‐year‐old woman with rheumatoid arthritis receiving long‐term adalimumab and methotrexate who developed disseminated TB with pulmonary, splenic, and ocular involvement after 12 years of anti–TNF‐ α therapy. Baseline screening had shown a negative tuberculin skin test and an indeterminate interferon‐ γ release assay. She presented with constitutional and respiratory symptoms, whereas chest computed tomography demonstrated diffuse micronodular infiltrates consistent with miliary TB. Microbiological confirmation was obtained via bronchoalveolar lavage. Ophthalmologic evaluation revealed bilateral choroidal granulomas with subretinal edema, leading to a diagnosis of ocular TB. Standard antitubercular therapy (ATT) was initiated but required modification due to drug‐induced liver injury. Adjunctive systemic corticosteroids were introduced after antimicrobial therapy and gradually tapered. The patient achieved progressive clinical, radiological, and ophthalmologic improvement, with gradual regression of choroidal lesions. Discussion: This case underscores the persistent long‐term risk of TB reactivation during prolonged anti–TNF‐ α therapy and highlights the limitations of current screening strategies in immunosuppressed patients. Ocular TB requires integration of systemic, clinical, and imaging findings; in this patient, microbiologically confirmed disseminated TB together with characteristic bilateral choroidal granulomas supported a definitive diagnosis. Management relies on prompt ATT, discontinuation of immunosuppression, and judicious use of adjunctive corticosteroids. Long‐term follow‐up is essential given the risk of persistent lesions and late recurrence. Reintroduction of biologic therapy may be feasible in selected cases but requires careful risk stratification. Conclusion: TB should remain a diagnostic consideration in patients receiving biologic therapy who develop compatible systemic or ocular manifestations, even after long‐term treatment and negative baseline screening. Close multidisciplinary collaboration is essential for the diagnosis and management of ocular TB in this population.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Hepatology
- Vol. 2026 (1) , 9286315
The Abscess That Was Cancer: Pyogenic Liver Abscess as the Initial Manifestation of Hepatocellular Carcinoma in a Noncirrhotic Patient
Background: Malignant and benign hepatic diseases may both present with systemic symptoms and necrotic liver cavities. Although rare and reported predominantly in East Asia, pyogenic liver abscess (PLA) can represent the initial manifestation of hepatocellular carcinoma (HCC), as necrotic tumors may mimic infectious abscesses. Case Presentation: A 63‐year‐old Italian man presented with a 2‐week history of fever and right upper quadrant pain. Computed tomography revealed a multiloculated lesion with irregular margins and a solid component in the right hepatic lobe, suggestive of a liver abscess, and empirical tigecycline therapy was initiated. Low‐titer Entamoeba spp. IgG antibodies were detected, and percutaneous aspiration yielded material initially mischaracterized as “anchovy paste,” raising suspicion for amoebic liver abscess. However, the patient failed to improve despite appropriate antiprotozoal therapy. Subsequent percutaneous drainage led to cavity resolution and symptom relief; all microbiological and parasitological tests were negative, and repeat Entamoeba serology became negative. Concurrent biopsy of the solid component revealed well‐differentiated pseudoglandular HCC. Magnetic resonance imaging demonstrated a biliary fistula associated with the neoplastic lesion, supporting a diagnosis of PLA secondary to HCC. The patient underwent right hepatectomy, complicated by intraoperative abscess rupture and postoperative intra‐abdominal abscesses caused by vancomycin‐resistant Enterococcus faecium . Discussion: PLA presenting as the initial manifestation of HCC is associated with poor prognosis, largely due to diagnostic delays. Limited clinical experience outside high‐prevalence regions and nonspecific clinical, laboratory, and imaging findings contribute to underrecognition of malignancy. Positive microbiological or serological results and transient clinical improvement during antimicrobial therapy do not exclude an underlying neoplasm. Liver biopsy and close radiologic follow‐up are essential in atypical or treatment‐refractory cases. Conclusion: PLA as a presenting feature of HCC is unusual, especially in Europe, yet poses substantial diagnostic and therapeutic challenges. Increased clinical awareness and early histopathological evaluation are crucial to avoid delayed oncologic diagnosis.
- 1 January 2026
- Published by Wiley in Case Reports in Hepatology
- Vol. 2026 (1) , 9286315
Open AccessThe Abscess That Was Cancer: Pyogenic Liver Abscess as the Initial Manifestation of Hepatocellular Carcinoma in a Noncirrhotic Patient
Background: Malignant and benign hepatic diseases may both present with systemic symptoms and necrotic liver cavities. Although rare and reported predominantly in East Asia, pyogenic liver abscess (PLA) can represent the initial manifestation of hepatocellular carcinoma (HCC), as necrotic tumors may mimic infectious abscesses. Case Presentation: A 63‐year‐old Italian man presented with a 2‐week history of fever and right upper quadrant pain. Computed tomography revealed a multiloculated lesion with irregular margins and a solid component in the right hepatic lobe, suggestive of a liver abscess, and empirical tigecycline therapy was initiated. Low‐titer Entamoeba spp. IgG antibodies were detected, and percutaneous aspiration yielded material initially mischaracterized as “anchovy paste,” raising suspicion for amoebic liver abscess. However, the patient failed to improve despite appropriate antiprotozoal therapy. Subsequent percutaneous drainage led to cavity resolution and symptom relief; all microbiological and parasitological tests were negative, and repeat Entamoeba serology became negative. Concurrent biopsy of the solid component revealed well‐differentiated pseudoglandular HCC. Magnetic resonance imaging demonstrated a biliary fistula associated with the neoplastic lesion, supporting a diagnosis of PLA secondary to HCC. The patient underwent right hepatectomy, complicated by intraoperative abscess rupture and postoperative intra‐abdominal abscesses caused by vancomycin‐resistant Enterococcus faecium . Discussion: PLA presenting as the initial manifestation of HCC is associated with poor prognosis, largely due to diagnostic delays. Limited clinical experience outside high‐prevalence regions and nonspecific clinical, laboratory, and imaging findings contribute to underrecognition of malignancy. Positive microbiological or serological results and transient clinical improvement during antimicrobial therapy do not exclude an underlying neoplasm. Liver biopsy and close radiologic follow‐up are essential in atypical or treatment‐refractory cases. Conclusion: PLA as a presenting feature of HCC is unusual, especially in Europe, yet poses substantial diagnostic and therapeutic challenges. Increased clinical awareness and early histopathological evaluation are crucial to avoid delayed oncologic diagnosis.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Infectious Diseases
- Vol. 2026 (1)
Candidemia Complicated by Mycotic Thrombus of the Femoral Artery in a Patient With Left Ventricular Assist Device
Background: Ventricular assist devices (VADs) are increasingly used as a bridge to transplantation or as destination therapy in heart failure patients. Fungal bloodstream infections, though less common than bacterial infections in VAD recipients, carry the highest mortality. Arterial involvement, including mycotic thrombus formation, is exceptionally rare and poses diagnostic and therapeutic challenges. We report the first documented case of candidemia complicated by femoral arterial mycotic thrombus in an LVAD recipient. Case Presentation: A 50‐year‐old man developed Candida albicans fungemia four months after undergoing LVAD implantation for severe dilated cardiomyopathy. Intravenous caspofungin was initiated due to potential azole–warfarin interactions. Blood cultures rapidly became negative, and multimodal imaging revealed no LVAD or endovascular involvement. On day 37 of ongoing antifungal therapy, ultrasound identified a subocclusive femoral artery thrombus at a prior cannulation site. Surgical thrombectomy confirmed C. albicans within the clot. Antifungal therapy continued, and the patient underwent successful emergency heart transplantation 15 days later. Discussion: Invasive fungal vascular infections may occur despite negative blood cultures and absence of detectable device involvement. Prior arterial trauma likely predisposed to localized fungal colonization. Management required careful risk assessment, prompt surgical intervention, and individualized antifungal therapy. Multidisciplinary collaboration among infectious disease specialists, radiologists, cardiologists, and cardiac surgeons was critical. Definitive source control through device explantation and transplantation was essential for curative intent. Device removal should be considered on a case‐by‐case basis, even when imaging shows no infectious foci, as prognosis without it may be poor. Fungal infection does not necessarily contraindicate transplantation, and early recognition combined with tailored therapy can optimize outcomes. Conclusions: Arterial Candida thrombus in LVAD recipients is rare but life‐threatening. High clinical suspicion, multimodal diagnostics, prompt surgical management, and individualized antifungal therapy are essential. Further studies are needed to define optimal antifungal strategies, surveillance, and transplant considerations for these high‐risk infections.
- 1 January 2026
- Published by Wiley in Case Reports in Infectious Diseases
- Vol. 2026 (1)
Open AccessCandidemia Complicated by Mycotic Thrombus of the Femoral Artery in a Patient With Left Ventricular Assist Device
Background: Ventricular assist devices (VADs) are increasingly used as a bridge to transplantation or as destination therapy in heart failure patients. Fungal bloodstream infections, though less common than bacterial infections in VAD recipients, carry the highest mortality. Arterial involvement, including mycotic thrombus formation, is exceptionally rare and poses diagnostic and therapeutic challenges. We report the first documented case of candidemia complicated by femoral arterial mycotic thrombus in an LVAD recipient. Case Presentation: A 50‐year‐old man developed Candida albicans fungemia four months after undergoing LVAD implantation for severe dilated cardiomyopathy. Intravenous caspofungin was initiated due to potential azole–warfarin interactions. Blood cultures rapidly became negative, and multimodal imaging revealed no LVAD or endovascular involvement. On day 37 of ongoing antifungal therapy, ultrasound identified a subocclusive femoral artery thrombus at a prior cannulation site. Surgical thrombectomy confirmed C. albicans within the clot. Antifungal therapy continued, and the patient underwent successful emergency heart transplantation 15 days later. Discussion: Invasive fungal vascular infections may occur despite negative blood cultures and absence of detectable device involvement. Prior arterial trauma likely predisposed to localized fungal colonization. Management required careful risk assessment, prompt surgical intervention, and individualized antifungal therapy. Multidisciplinary collaboration among infectious disease specialists, radiologists, cardiologists, and cardiac surgeons was critical. Definitive source control through device explantation and transplantation was essential for curative intent. Device removal should be considered on a case‐by‐case basis, even when imaging shows no infectious foci, as prognosis without it may be poor. Fungal infection does not necessarily contraindicate transplantation, and early recognition combined with tailored therapy can optimize outcomes. Conclusions: Arterial Candida thrombus in LVAD recipients is rare but life‐threatening. High clinical suspicion, multimodal diagnostics, prompt surgical management, and individualized antifungal therapy are essential. Further studies are needed to define optimal antifungal strategies, surveillance, and transplant considerations for these high‐risk infections.